GKOS / Glaukos Corporation - Документы SEC, Годовой отчет, Доверенное заявление

As filed with the Securities and Exchange Commission on August 20, 2025

As filed with the Securities and Exchange Commission on August 20, 2025 Registration No.

Table 1: Newly Registered Securities

Calculation of Filing Fee Tables S-8 GLAUKOS Corp Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, par value $0.

Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Th

Exhibit 99.1 August 2025 Investor Presentation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management’s current expectations, assumptions, estimates and beliefs. Alth

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 Glaukos Corporati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37463 GLAUKOS CORPORATION (Exact n

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2025 Glaukos Corporation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2025 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of inc

Glaucoma Corneal Health Retinal Disease

Exhibit 99.2 JULY 30, 2025 GLAUKOS CORPORATION (NYSE: GKOS) SECOND QUARTER 2025 IN REVIEW Important Information This document is intended to be read by investors in advance of regularly scheduled quarterly conference calls and was designed to provide a review of Glaukos Corporation’s recent financial and operational performance and general business outlook. Please see “Forward-Looking Statements”

Glaukos Announces Second Quarter 2025 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Chris Lewis Vice President, Investor Relations & Corporate Affairs (949) 481-0510 [email protected] Glaukos Announces Second Quarter 2025 Financial Results Aliso Viejo, CA – July 30, 2025 – Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2025 Glaukos Corporation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2025 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of inco

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Glaukos Corporation (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identification No.) One Glaukos Way Aliso Viejo, California 92656 (Address of principal executiv

Glaukos Corporation Conflict Minerals Report for the Year Ended December 31, 2024

Exhibit 1.01 Glaukos Corporation Conflict Minerals Report for the Year Ended December 31, 2024 Glaukos Corporation (“Glaukos,” “the Company,” “we,” “our,” and “us”) has filed this Conflict Minerals Report (“CMR”) for the year ended December 31, 2024 to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the “Rule”). The Rule imposes certain reporting obligations on U.S. Securities an

Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Th

Exhibit 99.1 May 2025 Investor Presentation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management’s current expectations, assumptions, estimates and beliefs. Althoug

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 Glaukos Corporation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of inco

Directors’ Compensation Policy adopted March 13, 2025

Exhibit 10.1 GLAUKOS CORPORATION DIRECTORS’ COMPENSATION POLICY (Effective December 13, 2017, Amended and Restated March 13, 2025) Directors of Glaukos Corporation, a Delaware corporation (the “Company”), who are not employed by the Company or one of its subsidiaries (“Non-Employee Directors”) are entitled to the compensation set forth below for their service as a member of the Board of Directors

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37463 GLAUKOS CORPORATION (Exact

Glaucoma Corneal Health Retinal Disease

APRIL 30, 2025 GLAUKOS CORPORATION (NYSE: GKOS) FIRST QUARTER 2025 IN REVIEW Important Information This document is intended to be read by investors in advance of regularly scheduled quarterly conference calls and was designed to provide a review of Glaukos Corporation’s recent financial and operational performance and general business outlook.

Glaukos Announces First Quarter 2025 Financial Results

FOR IMMEDIATE RELEASE Contact: Chris Lewis Vice President, Investor Relations & Corporate Affairs (949) 481-0510 clewis@glaukos.

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ◻ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2025 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of in

Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Th

Exhibit 99.1 March 2025 Investor Presentation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management’s current expectations, assumptions, estimates and beliefs. Altho

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No. 001-37463

Subsidiaries of Glaukos Corporation as of December 31, 2024

Exhibit 21 Subsidiaries Subsidiary Name State of Incorporation / Formation Country of Incorporation / Formation Glaukos Germany GmbH Germany Glaukos Japan GK Japan Glaukos Australia Pty Ltd Australia Glaukos Canada Inc.

Glaukos Corporation Insider Trading Policies and Procedures

EX-19 2 gkos-20241231xex19.htm EX-19 Exhibit 19 Glaukos Corporation Policy on Insider Trading and Tipping INTRODUCTION In the normal course of business, officers, directors and employees of Glaukos Corporation (“Company”) may come into possession of material nonpublic information. This information is considered the property of the Company. In particular, if you are an insider under the law or cove

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2025 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of

Glaucoma Corneal Health Retinal Disease

Exhibit 99.2 FEBRUARY 20, 2025 GLAUKOS CORPORATION (NYSE: GKOS) FOURTH QUARTER AND FULL YEAR 2024 IN REVIEW Important Information This document is intended to be read by investors in advance of regularly scheduled quarterly conference calls and was designed to provide a review of Glaukos Corporation’s recent financial and operational performance and general business outlook. Please see “Forward-Lo

Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Chris Lewis Vice President, Investor Relations & Corporate Affairs (949) 481-0510 [email protected] Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results Aliso Viejo, CA – February 20, 2025 – Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glauc

Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Th

Exhibit 99.1 January 2025 Investor Presentation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management’s current expectations, assumptions, estimates and beliefs. Alt

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2025 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2024 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2024 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of

Form of Capped Call Unwind Agreement, dated as of December 2, 2024, by and between Glaukos Corporation and the applicable call option counterparty

EX-10.1 2 gkos-20241202xex10d1.htm EX-10.1 Exhibit 10.1 UNWIND AGREEMENT dated as of [·], 202 Between Glaukos Corporation and [DEALER] THIS UNWIND AGREEMENT (this “Agreement”) with respect to the Capped Call Confirmations (as defined below) is made as of [·], 202, between Glaukos Corporation (“Company”) and [DEALER] (“Dealer”). WHEREAS, Company issued $287,500,000 aggregate principal amount of 2.7

Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Th

Exhibit 99.1 Investor Presentation November 2024 Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management’s current expectations, assumptions, estimates and beliefs. Al

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2024 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of

GKOS / Glaukos Corporation / BROWN CAPITAL MANAGEMENT LLC Passive Investment

SC 13G/A 1 fp0090934-5sc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 8)* Glaukos Corporation (Name of Issuer) Common Stock, $0.001 Par Value Per Share (Title of Class of Securities) 377322102 (C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37463 GLAUKOS CORPORATION (Ex

Glaukos Announces Third Quarter 2024 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Chris Lewis Vice President, Investor Relations & Corporate Affairs (949) 481-0510 [email protected] Glaukos Announces Third Quarter 2024 Financial Results Aliso Viejo, CA – November 4, 2024 – Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal dis

Glaucoma Corneal Health Retinal Disease

Exhibit 99.2 NOVEMBER 4, 2024 GLAUKOS CORPORATION (NYSE: GKOS) THIRD QUARTER 2024 IN REVIEW Important Information This document is intended to be read by investors in advance of regularly scheduled quarterly conference calls and was designed to provide a review of Glaukos Corporation’s recent financial and operational performance and general business outlook. Please see “Forward-Looking Statements

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2024 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2024 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of

NOTICE OF FULL REDEMPTION GLAUKOS CORPORATION 2.75% Convertible Senior Notes due 2027 CUSIP: 377322 AB8

NOTICE OF FULL REDEMPTION GLAUKOS CORPORATION 2.75% Convertible Senior Notes due 2027 CUSIP: 377322 AB8 NOTICE IS HEREBY GIVEN pursuant to Section 16.02 of the Indenture, dated as of June 11, 2020 (the “Indenture”), by and between Glaukos Corporation, as issuer (the “Company”), and Computershare Trust Company, National Association, as successor to Wells Fargo Bank, National Association, as trustee

Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Th

Exhibit 99.1 Investor Presentation August 2024 Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management’s current expectations, assumptions, estimates and beliefs. Alth

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2024 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37463 GLAUKOS CORPORATION (Exact n

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2024 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of i

GLAUKOS CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts)

Exhibit 99.1 GLAUKOS CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) (in thousands, except per share amounts) Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 Net sales $ 95,690 $ 80,399 $ 181,312 $ 154,298 Cost of sales 22,550 20,103 42,808 38,174 Gross profit 73,140 60,296 138,504 116,124 Operating expenses: Selling, general and administrative 66,

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2024 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of inc

Glaucoma Corneal Health Retinal Disease

Exhibit 99.2 JULY 31, 2024 GLAUKOS CORPORATION (NYSE: GKOS) SECOND QUARTER 2024 IN REVIEW Important Information This document is intended to be read by investors in advance of regularly scheduled quarterly conference calls and was designed to provide a review of Glaukos Corporation’s recent financial and operational performance and general business outlook. Please see “Forward-Looking Statements”

Glaukos Announces Second Quarter 2024 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Chris Lewis Vice President, Investor Relations & Corporate Affairs (949) 481-0510 [email protected] Glaukos Announces Second Quarter 2024 Financial Results Aliso Viejo, CA – July 31, 2024 – Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disor

Unregistered Sales of Equity Securities, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2024 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of inc

Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2024 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of inc

Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock

FOR IMMEDIATE RELEASE Contact: Chris Lewis Vice President, Investor Relations & Corporate Affairs (949) 481-0510 clewis@glaukos.

Glaukos Corporation Amended and Restated 2015 Omnibus Incentive Compensation Plan

Exhibit 10.1 GLAUKOS CORPORATION AMENDED AND RESTATED 2015 OMNIBUS INCENTIVE COMPENSATION PLAN 1.PURPOSE OF PLAN The purpose of this Amended and Restated 2015 Omnibus Incentive Compensation Plan (this “Plan”) of Glaukos Corporation, a Delaware corporation (the “Corporation”), is to promote the success of the Corporation by providing an additional means through the grant of awards to attract, motiv

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2024 Glaukos Corporation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2024 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of inco

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Glaukos Corporation (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identification No.) One Glaukos Way Aliso Viejo, California 92656 (Address of principal executiv

Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD

Exhibit 1.01 Glaukos Conflict Minerals Report for the Year Ended December 31, 2023 Glaukos Corporation (“Glaukos,” “the Company,” “we,” “our,” and “us”) has filed this Conflict Minerals Report (“CMR”) for the year ended December 31, 2023 to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the “Rule”). The Rule imposes certain reporting obligations on U.S. Securities and Exchange C

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2024 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of inco

Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Th

Exhibit 99.1 Investor Presentation May 2024 Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management’s current expectations, assumptions, estimates and beliefs. Althoug

Directors’ Compensation Policy adopted March 14, 2024

Exhibit 10.1 GLAUKOS CORPORATION DIRECTORS’ COMPENSATION POLICY (Effective December 13, 2017, Amended and Restated March 14, 2024) Directors of Glaukos Corporation, a Delaware corporation (the “Company”), who are not employed by the Company or one of its subsidiaries (“Non-Employee Directors”) are entitled to the compensation set forth below for their service as a member of the Board of Directors

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37463 GLAUKOS CORPORATION (Exact

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2024 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of incor

Glaucoma Corneal Health Retinal Disease

Exhibit 99.2 MAY 1, 2024 GLAUKOS CORPORATION (NYSE: GKOS) FIRST QUARTER 2024 IN REVIEW Important Information This document is intended to be read by investors in advance of regularly scheduled quarterly conference calls and was designed to provide a review of Glaukos Corporation’s recent financial and operational performance and general business outlook. Please see “Forward-Looking Statements” and

Glaukos Announces First Quarter 2024 Financial Results

EXHIBIT 99.1 FOR IMMEDIATE RELEASE Contact: Chris Lewis Vice President, Investor Relations & Corporate Affairs (949) 481-0510 [email protected] Glaukos Announces First Quarter 2024 Financial Results Aliso Viejo, CA – May 1, 2024 – Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorder

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ◻ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Glaukos Corporation (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.

As filed with the Securities and Exchange Commission on March 15, 2024

As filed with the Securities and Exchange Commission on March 15, 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 Glaukos Corpora

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of

Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Th

Exhibit 99.1 Investor Presentation February 2024 Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management’s current expectations, assumptions, estimates and beliefs. Al

Third Amendment to Lease dated as of January 25, 2024 between the Registrant and 229 Avenida, LLC.

Exhibit 10.23 THIRD AMENDMENT TO LEASE This Third Amendment To Lease (“Third Amendment”) is dated as of January 25, 2024 and is entered into by and between 229 Avenida, LLC, a California limited liability company (“Lessor”), and Glaukos Corporation, a Delaware corporation (“Lessee”). Recitals A.Lessee and Lessor’s predecessor in interest, 229 Fabricante, LLC, a California limited liability company

Subsidiaries of Glaukos Corporation as of December 31, 2023

Exhibit 21 Subsidiaries Subsidiary Name State of Incorporation / Formation Country of Incorporation / Formation Glaukos Germany GmbH Germany Glaukos Japan GK Japan Glaukos Australia Pty Ltd Australia Glaukos Canada Inc.

UNITED STATES

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No. 001-37463

Dodd-Frank Clawback Policy

Exhibit 97 Glaukos Corporation Dodd-Frank Clawback Policy Glaukos Corporation (“Company”) has adopted this clawback policy (this “Policy”) to replace and supersede any other clawback policies in effect now or in the future at the Company.

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2024 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of

Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results

FOR IMMEDIATE RELEASE Contact: Chris Lewis Vice President, Investor Relations & Corporate Affairs (949) 481-0510 clewis@glaukos.

Glaucoma Corneal Health Retinal Disease

FEBRUARY 21, 2024 GLAUKOS CORPORATION (NYSE: GKOS) FOURTH QUARTER & FULL YEAR 2023 IN REVIEW Important Information This document is intended to be read by investors in advance of regularly scheduled quarterly conference calls and was designed to provide a review of Glaukos Corporation’s recent financial and operational performance and general business outlook.

GKOS / Glaukos Corporation / BROWN CAPITAL MANAGEMENT LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 7)* Glaukos Corporation (Name of Issuer) Common Stock, $0.001 Par Value Per Share (Title of Class of Securities) 377322102 (CUSIP Number) Eddie C. Brown Brown

GKOS / Glaukos Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01023-glaukoscorp.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Glaukos Corp Title of Class of Securities: Common Stock CUSIP Number: 377322102 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule

GKOS / Glaukos Corporation / Burns Thomas William - SC 13G/A Passive Investment

SC 13G/A 1 tmb-20240213xsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 8)* Under the Securities Exchange Act of 1934 GLAUKOS CORPORATION (Name of Issuer) Common Stock (Title of Class of Securities) 377322102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d

GKOS / Glaukos Corporation / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Glaukos Corp (Name of Issuer) Common Stock (Title of Class of Securities) 377322102 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design

Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Th

Exhibit 99.2 Investor Presentation January 2024 Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management’s current expectations, assumptions, estimates and beliefs. Alt

Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Net Sales and Reaffirms 2024 Revenue Guidance

FOR IMMEDIATE RELEASE Investor Contact: Chris Lewis Vice President, Investor Relations & Corporate Affairs (949) 481-0510 clewis@glaukos.

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2024 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of i

© 2023 Glaukos Corporation Page 1 FDA Approval CONFERENCE CALL & WEBCAST December 14, 2023 (travoprost intracameral implant 75 mcg)

Exhibit 99.2 © 2023 Glaukos Corporation Page 1 FDA Approval CONFERENCE CALL & WEBCAST December 14, 2023 (travoprost intracameral implant 75 mcg) © 2023 Glaukos Corporation Page 2 © 2023 Glaukos Corporation Page 2 Glaukos Participants Tom Burns Chairman & CEO Joe Gilliam President & COO Alex Thurman Sr. VP & Chief Financial Officer Tomas Navratil, Ph.D. Chief Development Officer Chris Lewis VP, Inv

Glaukos Announces FDA Approval of iDose® TR (travoprost intracameral implant) Revolutionary, micro-invasive, injectable treatment for the full range of glaucoma disease severity iDose TR was designed to usher in a new era of interventional glaucoma b

Exhibit 99.1 FOR IMMEDIATE RELEASE Media Contact – Glaucoma: Stefanie Tuck (978) 390-1394 [email protected] Investor Contact: Chris Lewis Vice President, Investor Relations & Corporate Affairs (949) 481-0510 [email protected] Glaukos Announces FDA Approval of iDose® TR (travoprost intracameral implant) Revolutionary, micro-invasive, injectable treatment for the full range of glaucoma disease sever

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2023 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of

Glaukos Announces Third Quarter 2023 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Chris Lewis Vice President, Investor Relations & Corporate Affairs (949) 481-0510 [email protected] Glaukos Announces Third Quarter 2023 Financial Results Aliso Viejo, CA – November 1, 2023 – Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37463 GLAUKOS CORPORATION (Ex

Glaucoma Corneal Health Retinal Disease

Exhibit 99.2 NOVEMBER 1, 2023 GLAUKOS CORPORATION (NYSE: GKOS) THIRD QUARTER 2023 IN REVIEW Important Information This document is intended to be read by investors in advance of regularly scheduled quarterly conference calls and was designed to provide a review of Glaukos Corporation’s recent financial and operational performance and general business outlook. Please see “Forward-Looking Statements

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2023 Glaukos Corporati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2023 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of i

Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Th

Exhibit 99.1 Investor Presentation August 2023 Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management’s current expectations, assumptions, estimates and beliefs. Alth

Glaukos Announces Second Quarter 2023 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Chris Lewis Vice President, Investor Relations & Corporate Affairs (949) 481-0510 [email protected] Glaukos Announces Second Quarter 2023 Financial Results Aliso Viejo, CA – August 2, 2023 – Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal diso

AUGUST 2, 2023 2 SECOND QUARTER 2023 FINANCIAL RESULTS SUMMARY Business Description Ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel, dropless platform therapies designed to disrupt the conventi

Exhibit 99.2 AUGUST 2, 2023 1 GLAUKOS CORPORATION (NYSE: GKOS) SECOND QUARTER 2023 IN REVIEW Important Information This document is intended to be read by investors in advance of regularly scheduled quarterly conference calls and was designed to provide a review of Glaukos Corporation’s recent financial and operational performance and general business outlook. Please see “Forward-Looking Statement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37463 GLAUKOS CORPORATION (Exact n

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of in

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of inco

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Glaukos Corporation (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identification No.) One Glaukos Way Aliso Viejo, California 92656 (Address of principal executiv

Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD

Exhibit 1.01 Glaukos Conflict Minerals Report for the Year Ended December 31, 2022 Glaukos Corporation (“Glaukos,” “the Company,” “we,” “our,” and “us”) has filed this Conflict Minerals Report (“CMR”) for the year ended December 31, 2022 to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the “Rule”). The Rule imposes certain reporting obligations on U.S. Securities and Exchange C

Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Th

Exhibit 99.1 Investor Presentation May 2023 Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management’s current expectations, assumptions, estimates and beliefs. Althoug

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2023 Glaukos Corporation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2023 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of inco

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37463 GLAUKOS CORPORATION (Exact

1Q 2023 $73.9 million (+9% reported, +11% constant currency vs. 1Q 2022)

Exhibit 99.2 MAY 3, 2023 GLAUKOS CORPORATION (NYSE: GKOS) FIRST QUARTER 2023 IN REVIEW Important Information This document is intended to be read by investors in advance of regularly scheduled quarterly conference calls and was designed to provide a review of Glaukos Corporation’s recent financial and operational performance and general business outlook. Please see “Forward-Looking Statements” and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 Glaukos Corporation (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of incor

Glaukos Announces First Quarter 2023 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Chris Lewis Vice President, Investor Relations & Corporate Affairs (949) 481-0510 [email protected] Glaukos Announces First Quarter 2023 Financial Results Aliso Viejo, CA – May 3, 2023 – Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorder

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ◻ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Glaukos Corporation (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.

As filed with the Securities and Exchange Commission on March 10, 2023

As filed with the Securities and Exchange Commission on March 10, 2023 Registration No.

Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Th

Exhibit 99.1 Investor Presentation March 2023 Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management’s current expectations, assumptions, estimates and beliefs. Altho

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2023 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of inc

Subsidiaries of Glaukos Corporation as of December 31, 2022

Exhibit 21 Subsidiaries Subsidiary Name State of Incorporation / Formation Country of Incorporation / Formation Glaukos Germany GmbH Germany Glaukos Japan GK Japan Glaukos Australia Pty Ltd Australia Glaukos Canada Inc.

Directors’ Compensation Policy

Exhibit 10.19 GLAUKOS CORPORATION DIRECTORS’ COMPENSATION POLICY (Effective December 13, 2017, Amended and Restated December 15, 2022) Directors of Glaukos Corporation, a Delaware corporation (the “Company”), who are not employed by the Company or one of its subsidiaries (“Non-Employee Directors”) are entitled to the compensation set forth below for their service as a member of the Board of Direct

UNITED STATES

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No. 001-37463

FEBRUARY 22, 2023 2 FOURTH QUARTER & FULL YEAR 2022 FINANCIAL RESULTS SUMMARY Business Description Ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel, dropless platform therapies designed to disru

Exhibit 99.2 Exhibit 99.2 FEBRUARY 22, 2023 1 GLAUKOS CORPORATION (NYSE: GKOS) FOURTH QUARTER & FULL YEAR 2022 IN REVIEW Important Information This document is intended to be read by investors in advance of regularly scheduled quarterly conference calls and was designed to provide a review of Glaukos Corporation’s recent financial and operational performance and general business outlook. Please se

Glaukos Announces Fourth Quarter and Full Year 2022 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Chris Lewis Vice President, Investor Relations & Corporate Affairs (949) 481-0510 [email protected] Glaukos Announces Fourth Quarter and Full Year 2022 Financial Results Aliso Viejo, CA – February 22, 2023 – Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glauc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 Glaukos Corpora

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of

GKOS / Glaukos Corp / BROWN CAPITAL MANAGEMENT LLC Passive Investment

SC 13G/A 1 fp0081789-1sc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 6)* Glaukos Corporation (Name of Issuer) Common Stock, $0.001 Par Value Per Share (Title of Class of Securities) 377322102 (C

GKOS / Glaukos Corp / Burns Thomas William - SC 13G/A Passive Investment

SC 13G/A 1 tm236668d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 7)* Under the Securities Exchange Act of 1934 GLAUKOS CORPORATION (Name of Issuer) Common Stock (Title of Class of Securities) 377322102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi

GKOS / Glaukos Corp / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv0988-glaukoscorp.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Glaukos Corp. Title of Class of Securities: Common Stock CUSIP Number: 377322102 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule

GKOS / Glaukos Corp / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Glaukos Corp (Name of Issuer) Common Stock (Title of Class of Securities) 377322102 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design

Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward - looking statements .

Exhibit 99.1 Investor Presentation January 2023 Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward - looking statements .. These statements are based on management’s current expectations, assumptions, estimates and beliefs

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2023 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): December 15, 2022 Glaukos Corporation (Exact name of registrant as specified in its charter) ? Delaware 001-37463 33-0945406 (State or other jurisdiction ? (Commission ? (I.

Amended and Restated Bylaws of the Registrant

EX-3.1 2 gkos-20221215xex3d1.htm EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF GLAUKOS CORPORATION (amended and restated as of December 15, 2022) ARTICLE I — CORPORATE OFFICES 4 1.1 REGISTERED OFFICE 4 1.2 OTHER OFFICES 4 ARTICLE II — MEETINGS OF STOCKHOLDERS 4 2.1 PLACE OF MEETINGS 4 2.2 ANNUAL MEETING 4 2.3 SPECIAL MEETING 4 2.4 ADVANCE NOTICE PROCEDURES 4 2.5 NOTICE OF STOCKHOLDERS’ MEETING

2 © 2022 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are f

Exhibit 99.1 Investor Presentation NOVEMBER 2022 2 ? 2022 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward - looking statements .. These statements are based on management?s current expectations, assum

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2022 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Glaukos Corporation Announces Third Quarter 2022 Financial Results

FOR IMMEDIATE RELEASE Contact: Chris Lewis Vice President, Investor Relations & Corporate Affairs (949) 481-0510 clewis@glaukos.

3Q 2022 $71.3 million (-4.6% vs. 3Q 2021; -1.6% constant currency vs. 3Q 2021) (-1.9% vs. 2Q 2022; -0.7% constant currency vs. 2Q 2022)

Exhibit 99.2 ? NOVEMBER 2, 2022 ? GLAUKOS CORPORATION (NYSE: GKOS) THIRD QUARTER 2022 IN REVIEW ? Important Information This document is intended to be read by investors in advance of regularly scheduled quarterly conference calls and was designed to provide a review of Glaukos Corporation?s recent financial and operational performance and general business outlook. Please see ?Forward-Looking Stat

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): November 2, 2022 Glaukos Corporation (Exact name of registrant as specified in its charter) ? Delaware 001-37463 33-0945406 (State or other jurisdiction ? (Commission ? (I.R.S

2 © 2022 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are f

Exhibit 99.1 Investor Presentation SEPTEMBER 2022 2 ? 2022 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward - looking statements .. These statements are based on management?s current expectations, assu

Regulation FD Disclosure, Financial Statements and Exhibits

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): September 7, 2022 Glaukos Corporation (Exact name of registrant as specified in its charter) ? Delaware 001-37463 33-0945406 (State or other jurisdiction ? (Commission ? (I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

2Q 2022 $72.7 million (-7% vs. 2Q 2021; -5% constant currency vs. 2Q 2021) (+7% vs. 1Q 2022; +9% constant currency vs. 1Q 2022)

Exhibit 99.2 ? AUGUST 3, 2022 ? GLAUKOS CORPORATION (NYSE: GKOS) SECOND QUARTER 2022 IN REVIEW ? Important Information ? This document is intended to be read by investors in advance of regularly scheduled quarterly conference calls and was designed to provide a review of Glaukos Corporation?s recent financial and operational performance and general business outlook. Please see ?Forward-Looking Sta

Glaukos Corporation Announces Second Quarter 2022 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Chris Lewis Vice President, Investor Relations & Corporate Affairs (949) 481-0510 [email protected] Glaukos Corporation Announces Second Quarter 2022 Financial Results Aliso Viejo, CA ? August 3, 2022 ? Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma,

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): August 3, 2022 Glaukos Corporation (Exact name of registrant as specified in its charter) ? Delaware 001-37463 33-0945406 (State or other jurisdiction ? (Commission ? (I.R.S.

Submission of Matters to a Vote of Security Holders

? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): June 2, 2022 Glaukos Corporation (Exact name of registrant as specified in its charter) ? Delaware 001-37463 33-0945406 (State or other jurisdiction ? (Commission ? (I.R.S.

Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD

Exhibit 1.01 Glaukos Conflict Minerals Report for the Year Ended December 31, 2021 Glaukos Corporation (?Glaukos,? ?the Company,? ?we,? ?our,? and ?us?) has filed this Conflict Minerals Report (?CMR?) for the year ended December 31, 2021 to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the ?Rule?). The Rule imposes certain reporting obligations on U.S. Securities and Exchange C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Glaukos Corporation (Exact name of registrant as specified in its charter)

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Glaukos Corporation (Exact name of registrant as specified in its charter) ? Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identification No.) ? 229 Avenida Fabricante San Clemente, California 92672 (Address of pr

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2022 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of inco

Investor Presentation MAY 2022

EX-99.1 2 tm2216565d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Investor Presentation MAY 2022 2 © 2022 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward - looking statements . These statements are based on m

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Alex R. Thurman Executive Severance and Change in Control Agreement dated April 1, 2022 (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q (File No. 001-37463) filed on May 5, 2022).

? Exhibit 10.1 EXECUTIVE SEVERANCE & CHANGE IN CONTROL AGREEMENT THIS EXECUTIVE SEVERANCE AND CHANGE IN CONTROL AGREEMENT (the ?Agreement?) is made by and between Glaukos Corporation (the ?Company?), and Alex Thurman (?Executive?) as of April 1, 2022. In consideration of the mutual promises, covenants and obligations contained herein, the Company and Executive agree as follows: 1.At-Will Employmen

Tomas Navratil Executive Severance and Change in Control Agreement dated April 1, 2022 (incorporated by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q (File No. 001-37463) filed on May 5, 2022).

? Exhibit 10.2 EXECUTIVE SEVERANCE & CHANGE IN CONTROL AGREEMENT THIS EXECUTIVE SEVERANCE AND CHANGE IN CONTROL AGREEMENT (the ?Agreement?) is made by and between Glaukos Corporation (the ?Company?), and Tomas Navratil (?Executive?) as of April 1, 2022. This Agreement amends, restates, replaces and supersedes in its entirety that certain Executive Severance and Change in Control Agreement dated as

Glaukos Corporation Announces First Quarter 2022 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Chris Lewis Vice President, Investor Relations & Corporate Affairs (949) 481-0510 [email protected] ? Glaukos Corporation Announces First Quarter 2022 Financial Results San Clemente, CA ? May 4, 2022 ? Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, c

1Q 2022 $67.7 million (flat vs. 1Q 2021; +1% constant currency vs. 1Q 2021)

? Exhibit 99.2 ? ? MAY 4, 2022 ? GLAUKOS CORPORATION (NYSE: GKOS) FIRST QUARTER 2022 IN REVIEW Important Information This document is intended to be read by investors in advance of regularly scheduled quarterly conference calls and was designed to provide a review of Glaukos Corporation?s recent financial and operational performance and general business outlook. Please see ?Forward-Looking Stateme

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): May 4, 2022 Glaukos Corporation (Exact name of registrant as specified in its charter) ? Delaware 001-37463 33-0945406 (State or other jurisdiction ? (Commission ? (I.R.S. Emp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant ? ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant ? ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Glaukos Corporation (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 33-0945406 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 229 Avenida Fabricante San Clement

Power of Attorney (included in the Original Filing under “Signatures”).

As filed with the Securities and Exchange Commission on March 8, 2022 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Glaukos Corporation (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.

Investor Presentation MARCH 2022 2 © 2022 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will

Exhibit 99.1 Investor Presentation MARCH 2022 2 ? 2022 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward - looking statements .. These statements are based on management?s current expectations, assumpti

Regulation FD Disclosure, Financial Statements and Exhibits

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): March 2, 2022 Glaukos Corporation (Exact name of registrant as specified in its charter) ? Delaware 001-37463 33-0945406 (State or other jurisdiction ? (Commission ? (I.R.S.

Subsidiaries of Glaukos Corporation as of December 31, 2021

Exhibit 21 Subsidiaries Subsidiary Name State of Incorporation / Formation Country of Incorporation / Formation Glaukos Germany GmbH ? Germany Glaukos Japan GK ? Japan Glaukos Australia Pty Ltd ? Australia Glaukos Canada Inc.

UNITED STATES

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 10-K ? (Mark one) ? ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the fiscal year ended December 31, 2021 ? OR ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from: to ? Commission Fi

Directors’ Compensation Policy

? Exhibit 10.22 GLAUKOS CORPORATION DIRECTORS? COMPENSATION POLICY (Effective December 13, 2017, Amended and Restated December 16, 2021) Directors of Glaukos Corporation, a Delaware corporation (the ?Company?), who are not employed by the Company or one of its subsidiaries (?Non-Employee Directors?) are entitled to the compensation set forth below for their service as a member of the Board of Dire

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 22, 2022 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (IRS Employer of inc

Glaukos Corporation Announces Fourth Quarter and Full Year 2021 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Chris Lewis Vice President, Investor Relations & Corporate Affairs (949) 481-0510 [email protected] Glaukos Corporation Announces Fourth Quarter and Full Year 2021 Financial Results San Clemente, CA ? February 22, 2022 ? Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treat

4Q 2021 $73.2 million (flat vs. 4Q 2020)

Exhibit 99.2 FEBRUARY 22, 2022 GLAUKOS CORPORATION (NYSE: GKOS) FOURTH QUARTER AND FULL YEAR 2021 IN REVIEW Important Information This document is intended to be read by investors in advance of regularly scheduled quarterly conference calls and was designed to provide a review of Glaukos Corporation?s recent financial and operational performance and general business outlook. Please see ?Forward-Lo

GKOS / Glaukos Corp / Burns Thomas William - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 6)* Under the Securities Exchange Act of 1934 GLAUKOS CORPORATION (Name of Issuer) Common Stock (Title of Class of Securities) 377322102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch

GKOS / Glaukos Corp / BROWN CAPITAL MANAGEMENT LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 5)* Glaukos Corporation (Name of Issuer) Common Stock, $0.001 Par Value Per Share (Title of Class of Securities) 377322102 (CUSIP Number) Eddie C. Brown Brown

GKOS / Glaukos Corp / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Glaukos Corp. Title of Class of Securities: Common Stock CUSIP Number: 377322102 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule 13d-1(b) ??Rule 13d-

Glaukos Announces Executive Leadership Changes

? FOR IMMEDIATE RELEASE Media Contact: Cassandra Dump (619) 971-1887 Cassy@pascalecommunications.

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

\ ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): February 4, 2022 Glaukos Corporation (Exact name of registrant as specified in its charter) ? Delaware 001-37463 33-0945406 (State or other jurisdiction ? (Commission ? (I.R

Investor Presentation JANUARY 2022 2 © 2022 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate wi

Exhibit 99.1 Investor Presentation JANUARY 2022 2 ? 2022 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward - looking statements .. These statements are based on management?s current expectations, assump

Regulation FD Disclosure, Financial Statements and Exhibits

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): January 11, 2022 Glaukos Corporation (Exact name of registrant as specified in its charter) ? Delaware 001-37463 33-0945406 (State or other jurisdiction ? (Commission ? (I.R

GKOS / Glaukos Corp / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Glaukos Corp (Name of Issuer) Common Stock (Title of Class of Securities) 377322102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is

Glaukos Announces Retirement of William J. Link, Ph.D., as Chairman of the Board and Election of Thomas W. Burns as New Chairman and Mark J. Foley as Lead Independent Director

? FOR IMMEDIATE RELEASE ? Contact: Chris Lewis Sr. Director, Investor Relations & Corporate Strategy & Development (949) 481-0510 [email protected] ? Glaukos Announces Retirement of William J. Link, Ph.D., as Chairman of the Board and Election of Thomas W. Burns as New Chairman and Mark J. Foley as Lead Independent Director ? San Clemente, CA ? December 20, 2021 ? Glaukos Corporation (NYSE: GKOS)

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

\ ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): December 16, 2021 Glaukos Corporation (Exact name of registrant as specified in its charter) ? Delaware 001-37463 33-0945406 (State or other jurisdiction ? (Commission ? (I.

Regulation FD Disclosure, Financial Statements and Exhibits

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): November 22, 2021 Glaukos Corporation (Exact name of registrant as specified in its charter) ? Delaware 001-37463 33-0945406 (State or other jurisdiction ? (Commission ? (I.

1 © 2021 Glaukos Corporation Investor Relations Presentation NOVEMBER 2021 2 © 2021 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments

Exhibit 99.1 1 ? 2021 Glaukos Corporation Investor Relations Presentation NOVEMBER 2021 2 ? 2021 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on manag

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Financial Statements and Exhibits, Results of Operations and Financial Condition

? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): November 4, 2021 Glaukos Corporation (Exact name of registrant as specified in its charter) ? Delaware 001-37463 33-0945406 (State or other jurisdiction ? (Commission ? (I.R.S

Glaukos Corporation Announces Third Quarter 2021 Financial Results

? ? ? Exhibit 99.1 ? ? ? ? FOR IMMEDIATE RELEASE Contact: Chris Lewis Sr. Director, Investor Relations & Corporate Strategy & Development (949) 481-0510 [email protected] ? Glaukos Corporation Announces Third Quarter 2021 Financial Results San Clemente, CA ? November 4, 2021 ? Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies

Regulation FD Disclosure

\ ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): November 2, 2021 Glaukos Corporation (Exact name of registrant as specified in its charter) ? Delaware 001-37463 33-0945406 (State or other jurisdiction ? (Commission ? (I.R

Other Events

\ ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): September 14, 2021 Glaukos Corporation (Exact name of registrant as specified in its charter) ? Delaware 001-37463 33-0945406 (State or other jurisdiction ? (Commission ? (I

GKOS / Glaukos Corp / BROWN CAPITAL MANAGEMENT LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 4)* Glaukos Corporation (Name of Issuer) Common Stock, $0.001 Par Value Per Share (Title of Class of Securities) 377322102 (CUSIP Number) Eddie C. Brown Brown

Regulation FD Disclosure, Financial Statements and Exhibits

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): August 18, 2021 Glaukos Corporation (Exact name of registrant as specified in its charter) ? Delaware 001-37463 33-0945406 (State or other jurisdiction ? (Commission ? (I.R.

1 © 2021 Glaukos Corporation August 2021 2 © 2021 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticip

Exhibit 99.1 1 ? 2021 Glaukos Corporation August 2021 2 ? 2021 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management?s current expectations, assu

Financial Statements and Exhibits, Results of Operations and Financial Condition

? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): August 5, 2021 Glaukos Corporation (Exact name of registrant as specified in its charter) ? Delaware 001-37463 33-0945406 (State or other jurisdiction ? (Commission ? (I.R.S.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Form of Director and Executive Officer Indemnification Agreement (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q (File No. 333-37463) filed on August 5, 2021).

Exhibit 10.1 ? GLAUKOS CORPORATION ? INDEMNIFICATION AGREEMENT ? This Indemnification Agreement (this ? Agreement ?) is dated as of July 1, 2021 and is between Glaukos Corporation, a Delaware corporation (the ? Company ?), and William J. Link, Ph.D. (? Indemnitee ?). ? RECITALS ? A. Indemnitee?s service to the Company substantially benefits the Company. ? B. Individuals are reluctant to serve as d

Glaukos Corporation Announces Second Quarter 2021 Financial Results

Exhibit 99.1 ? FOR IMMEDIATE RELEASE Contact: Chris Lewis Sr. Director, Investor Relations & Corporate Strategy & Development (949) 481-0510 [email protected] ? ? Glaukos Corporation Announces Second Quarter 2021 Financial Results ? San Clemente, CA ? August 5, 2021 ? Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the t

Regulation FD Disclosure

\ ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): July 19, 2021 Glaukos Corporation (Exact name of registrant as specified in its charter) ? Delaware 001-37463 33-0945406 (State or other jurisdiction ? (Commission ? (I.R.S.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders

? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): June 3, 2021 Glaukos Corporation (Exact name of registrant as specified in its charter) ? Delaware 001-37463 33-0945406 (State or other jurisdiction ? (Commission ? (I.R.S.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Glaukos Corporation (Exact name of registrant as specified in its charter)

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM SD Specialized Disclosure Report ? Glaukos Corporation (Exact name of registrant as specified in its charter) ? Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identification No.) ? 229 Avenida Fabricante San Clemente, California 92672 (Address o

Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD

Exhibit 1.01 Glaukos Conflict Minerals Report for the Year Ended December 31, 2020 Glaukos Corporation (?Glaukos,? ?the Company,? ?we,? ?our,? and ?us?) has filed this Conflict Minerals Report (?CMR?) for the year ended December 31, 2020 to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the ?Rule?). The Rule imposes certain reporting obligations on U.S. Securities and Exchange C

Quarterly Report - 10-Q

Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Glaukos Corporation Announces First Quarter 2021 Financial Results

? FOR IMMEDIATE RELEASE Contact: Chris Lewis Sr. Director, Investor Relations, Corporate Strategy & Development (949) 481-0510 [email protected] ? ? Glaukos Corporation Announces First Quarter 2021 Financial Results ? San Clemente, CA ? May 5, 2021 ? Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glauco

Financial Statements and Exhibits, Results of Operations and Financial Condition

? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): May 5, 2021 Glaukos Corporation (Exact name of registrant as specified in its charter) ? Delaware 001-37463 33-0945406 (State or other jurisdiction ? (Commission ? (I.R.S. Emp

- DEF 14A

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant ? ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

- S-8

As filed with the Securities and Exchange Commission on March 11, 2021 Registration No.

Regulation FD Disclosure, Financial Statements and Exhibits

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): March 4, 2021 Glaukos Corporation (Exact name of registrant as specified in its charter) ? Delaware 001-37463 33-0945406 (State or other jurisdiction ? (Commission ? (I.R.S.

1 © 2021 Glaukos Corporation March 2021 2 © 2021 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipa

Exhibit 99.1 1 ? 2021 Glaukos Corporation March 2021 2 ? 2021 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management?s current expectations, assum

Annual Report - 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 10-K ? (Mark one) ? ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the fiscal year ended December 31, 2020 ? OR ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from: to ? Commission Fi

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

\ ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): February 26, 2021 Glaukos Corporation (Exact name of registrant as specified in its charter) ? Delaware 001-37463 33-0945406 (State or other jurisdiction ? (Commission ? (I.

Glaukos Appoints Denice Torres and Dr. Leana Wen to its Board of Directors

? FOR IMMEDIATE RELEASE Media Contact: Cassandra Dump (619) 971-1887 Cassy@pascalecommunications.

Description of Capital Stock of Glaukos Corporation (incorporated by reference to Exhibit 4.3 to the Annual Report on Form 10-K (File No. 001-37463) filed on March 1, 2021).

Exhibit 4.3 ? DESCRIPTION OF CAPITAL STOCK OF GLAUKOS CORPORATION ? References to ?we,? ?us? and ?our? in this section refer to Glaukos Corporation. ? General ? The following is a summary of the rights of our common stock and preferred stock, and of certain provisions of our restated certificate of incorporation (our ?certificate of incorporation?), our amended and restated bylaws (our ?bylaws?),

Subsidiaries of Glaukos Corporation as of December 31, 2020

Exhibit 21 Subsidiaries Subsidiary Name State of Incorporation / Formation Country of Incorporation / Formation Glaukos Germany GmbH ? Germany Glaukos Japan GK ? Japan Glaukos Australia Pty Ltd ? Australia Glaukos Canada Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): February 25, 2021 Glaukos Corporation (Exact name of registrant as specified in its charter) ? Delaware 001-37463 33-0945406 (State or other jurisdiction ? (Commission ? (I.R.

Glaukos Corporation Announces Fourth Quarter and Full Year 2020 Financial Results

EX-99.1 2 gkos-20210225xex99d1.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Chris Lewis Director, Investor Relations, Corporate Strategy & Development (949) 481-0510 [email protected] Glaukos Corporation Announces Fourth Quarter and Full Year 2020 Financial Results San Clemente, CA – February 25, 2021 – Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 3)* Glau

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 3)* Glaukos Corporation (Name of Issuer) Common Stock, $0.001 Par Value Per Share (Title of Class of Securities) 377322102 (CUSIP Number) Eddie C. Brown Brown

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 5)* Under the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 5)* Under the Securities Exchange Act of 1934 GLAUKOS CORPORATION (Name of Issuer) Common Stock (Title of Class of Securities) 377322102 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch

1 © 2021 Glaukos Corporation January 2021

Exhibit 99.2 1 © 2021 Glaukos Corporation January 2021 2 © 2021 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward - looking statements . These statements are based on management’s current expectations,

Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2020 Net Sales

Exhibit 99.1 FOR IMMEDIATE RELEASE Media Contact: Cassandra Dump (619) 971-1887 [email protected] Investor Contact: Chris Lewis Director, Investor Relations & Corporate Strategy & Development (949) 481-0510 [email protected] Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2020 Net Sales San Clemente, CA – January 13, 2021 – Glaukos Corporation (NYSE: GKOS), an

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2021 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)*

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Glaukos Corp. Title of Class of Securities: Common Stock CUSIP Number: 377322102 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2020 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of

Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K (File No. 001-37463) filed on December 21, 2022).

Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF GLAUKOS CORPORATION (amended and restated as of November 17, 2020) TABLE OF CONTENTS Page ARTICLE I — CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II — MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES 1 2.5 NOTICE OF STOCKHOLDERS’ MEETINGS 6 2.6 QUORUM 7

Regulation FD Disclosure, Financial Statements and Exhibits

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): November 10, 2020 Glaukos Corporation (Exact name of registrant as specified in its charter) ? Delaware 001-37463 33-0945406 (State or other jurisdiction ? (Commission ? (I.

1 © 2020 Glaukos Corporation 1 November 2020 2 © 2020 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or ant

Exhibit 99.1 1 ? 2020 Glaukos Corporation 1 November 2020 2 ? 2020 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management?s current expectations,

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 Or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37463 GLAUKOS CORPORATION (Ex

Financial Statements and Exhibits, Results of Operations and Financial Condition

? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): November 5, 2020 Glaukos Corporation (Exact name of registrant as specified in its charter) ? Delaware 001-37463 33-0945406 (State or other jurisdiction ? (Commission ? (I.R.S

Glaukos Corporation Announces Third Quarter 2020 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Chris Lewis Director, Investor Relations, Corporate Strategy & Development (949) 481-0510 [email protected] Glaukos Corporation Announces Third Quarter 2020 Financial Results San Clemente, CA – November 5, 2020 – Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of

First Amendment to Office Building Lease dated as of December 12, 2018 between the Registrant and CIP 2014/SG Aliso Owner, LLC (incorporated by reference to Exhibit 10.5 to the Quarterly Report on Form 10-Q (File No. 001-37463) filed on August 7, 2020).

Exhibit 10.5 FIRST AMENDMENT TO OFFICE BUILDING LEASE THIS FIRST AMENDMENT TO OFFICE BUILDING LEASE ("Amendment") is made as of this 12th day of December, 2018, by and between CIP 2014/SG ALISO OWNER, LLC, a Delaware limited liability company ("Landlord"), and GLAUKOS CORPORATION, a Delaware corporation ("Tenant"). RECITALS A.Landlord and Tenant entered into that certain Office Building Lease date

First Amendment to Lease dated as of December 31, 2018 between the Registrant and 229 Avenida Fabricante, LLC (incorporated by reference to Exhibit 10.3 to the Quarterly Report on Form 10-Q (File No. 001-37463) filed on August 7, 2020).

Exhibit 10.3 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE ("First Amendment") is made and entered into as of the 21st day of December 2018 by and between 229 Avenida Fabricante, LLC, a California limited liability company ("Lessor") and Glaukos Corporation (“Lessee”). R E C I T A L S : A.Lessee and Lessor’s predecessor in interest, 229 Fabricante, LLC a California limited liability compa

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 Or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37463 GLAUKOS CORPORATION (Exact n

Second Amendment to Office Building Lease dated as of May 20, 2020 between the Registrant and CIP 2014/SG Aliso Owner, LLC (incorporated by reference to Exhibit 10.6 to the Quarterly Report on Form 10-Q (File No. 001-37463) filed on August 7, 2020).

Exhibit 10.6 SECOND AMENDMENT TO OFFICE BUILDING LEASE THIS SECOND AMENDMENT TO OFFICE BUILDING LEASE (“Amendment”) is made as of this 20th day of May, 2020, by and between CIP 2014 SG ALISO OWNER LLC, a Delaware limited liability company (“Landlord”), and GLAUKOS CORPORATION, a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant entered into that certain Office Building Lease dated N

Second Amendment to Lease dated as of July 2, 2020 between the Registrant and 229 Avenida Fabricante, LLC (incorporated by reference to Exhibit 10.4 to the Quarterly Report on Form 10-Q (File No. 001-37463) filed on August 7, 2020).

Exhibit 10.4 SECOND AMENDMENT TO LEASE This Second Amendment To Lease ("Second Amendment") is dated as of July 2, 2020 and is entered into by and between 229 Avenida Fabricante, LLC, a California limited liability company ("Lessor"), and Glaukos Corporation, a Delaware corporation (“Lessee”). Recitals A.Lessee and Lessor’s predecessor in interest, 229 Fabricante, LLC a California limited liability

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2020 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I

Glaukos Corporation Announces Second Quarter 2020 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Chris Lewis Director, Investor Relations, Corporate Strategy & Development (949) 481-0510 [email protected] Glaukos Corporation Announces Second Quarter 2020 Financial Results San Clemente, CA – August 6, 2020 – Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of g

Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2020 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of in

Form of Capped Call Confirmation (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K (File No. 001-37463) filed on June 12, 2020).

Exhibit 10.1 [] 1 To: Glaukos Corporation 229 Avenida Fabricante San Clemente, CA 92672 From: [] Re: [Base]2[Additional]3 Capped Call Transaction Ref. No: []4 Date: [], 2020 Dear Ladies and Gentlemen: The purpose of this communication (this “Confirmation”) is to set forth the terms and conditions of the above-referenced transaction entered into on the Trade Date specified below (the “Transaction”)

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2020 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of inco

Indenture, dated as of June 11, 2020, between Glaukos Corporation and Wells Fargo Bank, National Association, as trustee (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K (File No. 001-37463) filed on June 12, 2020).

Exhibit 4.1 EXECUTION VERSION GLAUKOS CORPORATION AND WELLS FARGO BANK, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of June 11, 2020 2.75% Convertible Senior Notes due 2027 TABLE OF CONTENTS Page Article 1 Definitions Section 1.01. Definitions 1 Section 1.02. References to Interest 13 Article 2 Issue, Description, Execution, Registration and Exchange of Notes Section 2.01. Designation and

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2020 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of inco

Glaukos Corporation Announces Proposed Private Offering of $200 Million of Convertible Senior Notes

Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Chris Lewis Director, Investor Relations, Corporate Strategy & Development (949) 481-0510 [email protected] Glaukos Corporation Announces Proposed Private Offering of $200 Million of Convertible Senior Notes San Clemente, CA – June 8, 2020 – Glaukos Corporation (NYSE: GKOS) (the “Company” or “Glaukos”), an ophthalmic medical technology and pharmaceutica

Glaukos Corporation Announces Pricing of Private Offering of $250 Million of 2.75% Convertible Senior Notes

Exhibit 99.2 FOR IMMEDIATE RELEASE Contact: Chris Lewis Director, Investor Relations, Corporate Strategy & Development (949) 481-0510 [email protected] Glaukos Corporation Announces Pricing of Private Offering of $250 Million of 2.75% Convertible Senior Notes San Clemente, CA – June 8, 2020 – Glaukos Corporation (NYSE: GKOS) (the “Company” or “Glaukos”), an ophthalmic medical technology and pharm

UNAUDITED PRO FORMA COMBINED STATEMENT OF OPERATIONS

Exhibit 99.3 UNAUDITED PRO FORMA COMBINED STATEMENT OF OPERATIONS On August 7, 2019, Glaukos Corporation (the Company or Glaukos) entered into an Agreement and Plan of Merger (Merger Agreement) with Atlantic Merger Sub, Inc. (Merger Sub) and Avedro, Inc. (Avedro) pursuant to which Merger Sub would merge with and into Avedro, with Avedro continuing as the surviving corporation and a wholly owned su

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2020 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of inco

FINANCIAL STATEMENTS OF AVEDRO Report of Independent Registered Public Accounting Firm

Exhibit 99.1 FINANCIAL STATEMENTS OF AVEDRO Report of Independent Registered Public Accounting Firm To the Stockholders and the Board of Directors of Avedro, Inc. Opinion on the Financial Statements We have audited the accompanying balance sheets of Avedro, Inc. (the "Company") as of December 31, 2018 and 2017, the related statements of operations, convertible preferred stock and stockholders' def

PART I—FINANCIAL INFORMATION

Exhibit 99.2 PART I—FINANCIAL INFORMATION Item 1. Financial Statements. Avedro, Inc. Condensed Balance Sheets (amounts in thousands except share data) (unaudited) September 30, December 31, 2019 2018 ASSETS Current assets: Cash and cash equivalents $ 52,146 $ 9,769 Accounts receivable, net (a) 12,328 4,725 Inventories 4,482 4,259 Prepaid expenses and other current assets 3,264 1,919 Total current

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2020 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of inco

- SD

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identification No.) 229 Avenida Fabricante San Clemente, California 92672 (Address of principal

1 © 2020 Glaukos Corporation 1 May 2020 3 © 2020 Glaukos Corporation 1 FY2014 sales; FY2019 sales; 2 FY2014 gross margin; FY2019 non-GAAP gross margin; 3 2015 as of 6/30/2015 (post-IPO); 2019 as of 12/31/2019; 4 12/31/2019 includes former Avedro empl

Exhibit 99.1 1 © 2020 Glaukos Corporation 1 May 2020 2 © 2020 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management’s current expectations, assum

Financial Statements and Exhibits, Other Events

\ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2020 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of in

GKOS / Glaukos Corp. / Alger Associates Inc - SC 13G/A Passive Investment

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Glaukos Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 377322102 (CUSIP Number) April 30, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th

Directors’ Compensation Policy

GLAUKOS CORPORATION DIRECTORS’ COMPENSATION POLICY (Effective March 12, 2020) Directors of Glaukos Corporation, a Delaware corporation (the “Company”), who are not employed by the Company or one of its subsidiaries (“Non-Employee Directors”) are entitled to the compensation set forth below for their service as a member of the Board of Directors (the “Board”) of the Company.

Glaukos Corporation Announces First Quarter 2020 Financial Results

EX-99.1 2 gkos-20200507xex99d1.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Chris Lewis Director, Investor Relations, Corporate Strategy & Development (949) 481-0510 [email protected] Glaukos Corporation Announces First Quarter 2020 Financial Results San Clemente, CA – May 7, 2020 – Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2020 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of incor

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 Or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37463 GLAUKOS CORPORATION (Exact

- DEF 14A

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

-

April 23, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Re: Glaukos Corporation Form 10-K for the Fiscal Year Ended December 31, 2019 Filed March 2, 2020 File No. 001-37463 Ladies and Gentlemen: We received your letter dated April 13, 2020 (the ?Letter?) setting forth a comment of the staff (th

Glaukos Provides Update on COVID-19 Impact and Preliminary Net Sales Range for the First Quarter of 2020

FOR IMMEDIATE RELEASE Investor Contact Chris Lewis Director, Investor Relations, Corporate Development & Strategy 949-481-0510 clewis@glaukos.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2020 Glaukos Corporation (Exact name of registrant as specified in its charter) Delaware 001-37463 33-0945406 (State or other jurisdiction (Commission (I.R.S. Employer of inc

Glaukos Provides COVID-19 Pandemic Update

Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact Chris Lewis Director, Investor Relations, Corporate Development & Strategy 949-481-0510 [email protected] Media Contact Cassandra Dump 619-971-1887 [email protected] Glaukos Provides COVID-19 Pandemic Update San Clemente, CA – March 24, 2020 – Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical com